Be sure to RSVP to join STAT reporters at STAT@ASH on December 7 for expert-led discussions on the future of hematology and cancer research.
NEW SESSION | The Future of Blood Cancer Drugs
New technologies – bispecific antibodies, antibody-drug conjugates, and precision medicines – are reshaping the way hematological cancers are treated. Hear executives at the forefront of drug development discuss how these technologies are fueling a new era in cancer and beyond.
Susan Galbraith, Ph.D., executive vice-president, oncology R&D, AstraZeneca
Andres Sirulnik, M.D., Ph.D., SVP, hematology clinical development unit head, Regeneron
Jonathan Wosen, Ph.D., West Coast biotech & life sciences reporter, STAT (moderator)
Additional speakers to be announced
This event is free to attend. RSVP to reserve your spot!
%20MH%20Testing/Larger%20Header%20Logos/STAT_Events2.png?height=88&upscale=true&name=STAT_Events2.png){kind=small}
.jpg?width=1200&upscale=true&name=STAT@ASH_Marketing_EmailTall_Dark%20(1).jpg)
%20MH%20Testing/Footer%20Icons/Flipboard-logo.png?width=60&height=60&upscale=true&name=Flipboard-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/X-logo.png?width=60&height=60&upscale=true&name=X-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Linkedin-logo.png?width=60&height=60&upscale=true&name=Linkedin-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Facebook-logo.png?width=60&height=60&upscale=true&name=Facebook-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Youtube-logo.png?width=60&height=60&upscale=true&name=Youtube-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Instagram-logo.png?width=60&height=60&upscale=true&name=Instagram-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Threads-logo.png?width=60&height=60&upscale=true&name=Threads-logo.png){kind=logo}
No comments